此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

评估 LivPhcD 胶囊在 NAFLD 受试者中的疗效和安全性

2026年9月29日 更新者:TCM Biotech International Corp.

评估 LivPhcD 胶囊对 NAFLD 受试者疗效和安全性的多中心、随机、双盲、安慰剂对照研究

Non-alcoholic fatty liver disease (also called NAFLD) is a disease in which excessive fat accumulates in the liver of a patient without a history of alcohol abuse. Early-stage NAFLD does not usually cause any harm but nonalcoholic steatohepatitis (NASH) can lead to serious liver damage, including fibrosis or cirrhosis. Nearly 25% of the world's population is affected by NAFLD.

There are no FDA-approved medications for the treatment of NAFLD currently and although lifestyle modifications with appropriate diet and exercise have been shown to be beneficial, this has been difficult to achieve and sustain for the majority of patients.

LivPhcD™ capsule have shown hepatoprotective effects in both animal and human data. This study aims to investigate the effects of LivPhcD™ capsule in hepatocellular lipid content using Fibroscan.

研究概览

研究类型

介入性

注册 (实际的)

110

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Not Required For This Country
      • Taipei、Not Required For This Country、台湾、221
        • National Taiwan University Hospital

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

20年 至 75年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Male or female between 20 and 75 years of age.
  2. Capable of giving written informed consent and able to effectively communicate with the investigator and study personnel.
  3. Has a body mass index (BMI) ≥20 kg/m^2 and ≤50 kg/m^2 and stable weight for the past 3 months
  4. CAP ≥ 238 db/m
  5. Fibro scan (transient elastography) F0~F3

Exclusion Criteria:

  1. Pregnant or breastfeeding or planning to become pregnant or unwilling to use an acceptable contraceptive method to avoid pregnancy during the study period
  2. Type 1 diabetes mellitus.
  3. History of other causes of chronic liver disease [autoimmune, primary biliary cirrhosis, HBV (HBsAg positive) and HCV, Wilson disease, alpha-1-antitrypsin deficiency, hemochromatosis etc.
  4. Use of medications that could induce steatosis, such as estrogen or other hormonal replacement therapy, amiodarone, methotrexate, tamoxifen, raloxifene, pharmacological doses of oral glucocorticoids (≥10 mg per day of prednisone or equivalent), or chloroquine.
  5. Use of vitamin E (doses ≥800 IU/dy) or pioglitazone or SGLT2 inhibitor or GLP-1 agonists any FDA-approved drug for NASH to be approved during the study.
  6. Has significant systemic or major illnesses other than liver disease, ex: recent events (≤6 months before study entry) of congestive heart failure, unstable coronary artery disease, serious COPD, renal failure and need hemodialysis, stroke, transient ischemic attack, or organ transplantation
  7. Known alcohol abuse or alcohol use disorder (>20 g/day for women; >30 g/day for men)
  8. Has the abnormal data including: fasting TG >400 mg/dL ; ALT or GGT>5.0 x ULN;Bilirubin >2 x ULN,unless due to an alternative etiology such as Gilbert's syndrome; INR ≥1.3; Albumin < LLN; Platelet <0.95x LLN
  9. Subjects with hemoglobin A1c (HbA1c) >8.5% within 3 months before study entry
  10. Plan to have major surgery during the study period (bariatric surgery, biliary diversion surgery)
  11. Participation in any other investigational clinical trial within 30 days of entry to this protocol(including drugs, medical devices, novel medical technologies, food, and lifestyle interventions affecting diet, exercise, and circadian rhythm investigational clinical trial.);
  12. History of HIV

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
安慰剂比较:Placebo

Placebo without active ingredient

Placebo matching LivPhcD cap.

有源比较器:2 cap.LivPhcD/per day

515mg/LivPhcD cap. 2 cap./per day

2 caps. LivPhcD cap. after meal, once a day

有源比较器:4 cap.LivPhcD/per day

515mg/LivPhcD cap. 4 cap./per day, BID

4 caps. LivPhcD cap. after meal, BID

有源比较器:6 cap.LivPhcD/per day

515mg/LivPhcD cap. 6 cap./per day, TID

6 caps. LivPhcD cap. after meal, TID

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Reduction of Liver Fat
大体时间:36 weeks

Between group difference in the proportion of patients with ≥ 10% reduction of baseline of liver fat by CAP(Controlled Attenuation Parameter)

36 weeks

次要结果测量

结果测量
措施说明
大体时间
Change in liver fat at least 30% reduction
大体时间:24 weeks and 36 weeks

Between group difference in the proportion of patients with ≥ 30% reduction of baseline of liver fat by CAP

24 weeks and 36 weeks
Change in liver fat at least 1 stage reduction
大体时间:24 weeks and 36 weeks

Between group difference in the proportion of patients with 1 stage reduction of baseline of liver fat by CAP

24 weeks and 36 weeks
Change in liver fat
大体时间:24 weeks and 36 weeks

Between group difference in mean change of liver fat by CAP

24 weeks and 36 weeks
Stable in liver fat
大体时间:24 weeks and 36 weeks

Between group difference in the proportion of patients with stable of baseline of liver fat by CAP

24 weeks and 36 weeks
Change in liver fibrosis at least 10% reduction
大体时间:24 weeks and 36 weeks

Between group difference in the proportion of patients with ≥ 10% reduction of baseline of liver fibrosis by Fibroscan

24 weeks and 36 weeks
Change in liver fibrosis at least 1 stage reduction
大体时间:24 weeks and 36 weeks

Between group difference in the proportion of patients with 1 stage reduction of baseline of liver fibrosis by Fibroscan

24 weeks and 36 weeks
Stable in liver fibrosis
大体时间:24 weeks and 36 weeks

Between group difference in the proportion of patients with stable reduction of baseline of liver fibrosis by Fibroscan

24 weeks and 36 weeks
Change in liver fibrosis
大体时间:24 weeks and 36 weeks

Between group difference in mean change of FIB-4

24 weeks and 36 weeks
Change in ALT
大体时间:24 weeks and 36 weeks

Between group difference in mean change or in the proportion of patients of ALT

24 weeks and 36 weeks
Change in AST
大体时间:24 weeks and 36 weeks

Between group difference in mean change or in the proportion of patients of AST

24 weeks and 36 weeks
Change in GGT
大体时间:24 weeks and 36 weeks

Between group difference in mean change or in the proportion of patients of GGT

24 weeks and 36 weeks
Change in AP
大体时间:24 weeks and 36 weeks

Between group difference in mean change or in the proportion of patients of AP

24 weeks and 36 weeks
Change in Bilirubin
大体时间:24 weeks and 36 weeks

Between group difference in mean change or in the proportion of patients of Bilirubin

24 weeks and 36 weeks
Change in Triglyceride
大体时间:24 weeks and 36 weeks

Between group difference in mean change or in the proportion of patients of Triglyceride

24 weeks and 36 weeks
Change in Total Cholesterol
大体时间:24 weeks and 36 weeks

Between group difference in mean change or in the proportion of patients of Total Cholesterol

24 weeks and 36 weeks
Change in HDL-C
大体时间:24 weeks and 36 weeks

Between group difference in mean change or in the proportion of patients of HDL-C

24 weeks and 36 weeks
Change in LDL-C
大体时间:24 weeks and 36 weeks

Between group difference in mean change or in the proportion of patients of LDL-C

24 weeks and 36 weeks
Change in TNF-α
大体时间:24 weeks and 36 weeks

Between group difference in mean change or in the proportion of patients of TNF-α

24 weeks and 36 weeks
Change in C-Reactive Protein
大体时间:24 weeks and 36 weeks

Between group difference in mean change or in the proportion of patients of C-Reactive Protein

24 weeks and 36 weeks
Change in Albumin
大体时间:24 weeks and 36 weeks

Between group difference in mean change or in the proportion of patients of Albumin

24 weeks and 36 weeks
Occurrence of adverse events and serious adverse events
大体时间:24 weeks and 36 weeks

Between group difference in the occurrence of adverse events and serious adverse events.

24 weeks and 36 weeks

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2023年12月7日

初级完成 (实际的)

2025年12月22日

研究完成 (实际的)

2026年1月22日

研究注册日期

首次提交

2023年5月28日

首先提交符合 QC 标准的

2023年6月25日

首次发布 (实际的)

2023年7月5日

研究记录更新

最后更新发布 (实际的)

2026年10月2日

上次提交的符合 QC 标准的更新

2026年9月29日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

其他研究编号

  • LivPhcD-001

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅